To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
This study has been completed.
Information provided by (Responsible Party):
First received: October 7, 2009
Last updated: January 29, 2013
Last verified: January 2013
The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- PET Measurements [ Time Frame: Day 1 and Day 7 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2010|
|Study Completion Date:||August 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
Contacts and Locations